Effects of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) Therapy on miRNAs Expression and Absolute Microvascular Resistance by Continuous Thermodilution in ST-segment Elevation Myocardial Infarction (STEMI) Patients: PiCSO-STEMI TRIAL

Exclusion Criteria

• •1. Contraindication to coronary angiogram or PCI.
• •2. Implants or foreign bodies in the coronary sinus.
• •3. Known allergies to polyurethanes, Polyethylene Terephthalate (PET) or stainless steel.
• •4. Known pregnancy or breastfeeding.
• •5. Known coagulopathy.
• •6. Known severe kidney disease (eGFR \<=30 mL/min/1.73) and/or hemodialysis.
• •7. Known large pericardial effusion or cardiac tamponade.
• •8. Central hemodynamically relevant left-right shunt.
• •9. Previous MI or Coronary Artery Bypass Graft (CABG).
• •10. Previous history of stroke, transient ischemic attack (TIA) or reversible ischemic neurological deficit within last 6 months.
• •11. Cardiopulmonary resuscitated (CPR) cardiac arrest ≥ 5 minutes whom baseline neurologic status is not present.
• •12. Unconscious at presentation.
• •13. Need for circulatory support.
• •14. Need for invasive mechanical ventilation.
• •15. Need for temporal intravenous pacemaker.
• •16. Patient not suitable for femoral access.
• •17. Known contraindication for adenosine administration (severe asthma, complicated Atrioventricular (AV) block, critical aortic stenosis, severe cardiac arrhythmias, severe valve diseases).
• •18. Known epicardial stenosis greater than 50% distal to the culprit LAD lesion.
• •19. Active participation in another drug or device investigational trial.
• •20. Medical, social or psychological condition that limits the ability of patient to participate in the study.
• •21. Patients with definite or probable coronavirus disease 19 diagnosis within 2 weeks prior to STEMI.